Divi's Laboratories Limited (DIVISLAB) Earnings Call Transcripts

Divi's Laboratories Limited's Latest Earnings Call - Q4 FY2026

Divi's Laboratories Limited reported its Q4 FY '25-'26 earnings, highlighting a consolidated total income of INR 2,986 crores and a profit after tax of INR 751 crores. The company experienced a steady demand across its key segments despite geopolitical tensions affecting supply chains. Management emphasized the stability in their generic and custom synthesis businesses, with a constant currency growth of 6.82% for the year. However, the pricing environment remains competitive. The company capitalized assets worth INR 1,544 crores during the year, with a significant portion in the last quarter. Management maintained a cautious outlook due to ongoing supply chain challenges but expressed confidence in their strategic investments and operational resilience.

Reported metrics

Guidance from management

Management maintained a cautious outlook due to ongoing supply chain challenges but expressed confidence in achieving double-digit revenue growth. No specific margin guidance was provided due to market uncertainties.

What management said

See, right now, as we have shared, the capital work in progress is about INR 2,113 crores. And in fact, at Kakinada, we did mention earlier that we are going to do a INR 1,500 crores expansion plan, out of which INR 600 crores has been capitalized. So there is a lot of work in progress currently. And as and when we see an opportunity where there is material disclosure, we would definitely share it in the SEBI. Now co...

I mean with the changes in scenarios, I would say it's difficult to project, but we would say it would remain stable. And we would -- like it's also with the situation we are currently in, we wouldn't want to throw a figure on that.

What analysts pressed on

Analysts expressed concerns about the impact of rising raw material costs and the ability to pass these costs onto customers, particularly in the generic segment. There were also questions about the timeline for revenue recognition from recent CapEx investments and the potential impact on margins.

Main topics on the call

• Supply Chain Challenges — Management reported disruptions due to geopolitical tensions affecting logistics and raw material availability. Despite these challenges, they managed to maintain supply reliability. 'We are having difficulty in sourcing...
• Generic Business Stability — The generic business maintained stable volumes, but faced pricing pressures. Management noted, 'While the pricing environment remains competitive, we have seen steady demand across markets.'
• Custom Synthesis Segment — Customer engagement remained strong with a diversified product offering. Management highlighted, 'Our project pipeline remains active with molecules progressing through development to near commercialization.'
• Peptide Business Expansion — The company deepened its capabilities in the peptide segment, validating several fragments. 'We continue to invest in the capacity required to meet customer and portfolio-specific needs.'

Read the full Divi's Laboratories Limited transcript (Q4 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 23 Divi's Laboratories Limited earnings call transcripts on record, spanning August 8, 2020 to August 1, 2026. Based on this history, Divi's Laboratories Limited reports quarterly. The most recent call on file is dated August 1, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

DIVISLAB

Exchange

NSEI

Country

IN

Sector

Health Care

Industry

Life Sciences Tools and Services

Calls on record

23

First call

August 8, 2020

Most recent

August 1, 2026

Reporting cadence

quarterly